drugset / Trial / NCT00760214

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

NCT00760214

Phase 3 Completed 885 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.

Timeline

Start
2008-01
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Comparator Ramipril Small molecule 10 mg Oral

Indications